GH RESEARCH PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.51 USD | +0.10% |
|
-4.71% | +81.21% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 547M 43.75B |
|---|---|---|---|---|---|
| Net income 2024 * | -51M -4.08B | Net income 2025 * | -77M -6.16B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 324M 25.89B | Net cash position 2025 * | 267M 21.38B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-11.2
x | P/E ratio 2025 * |
-8.31
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.61% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.10% | ||
| 1 week | -4.71% | ||
| Current month | -1.41% | ||
| 1 month | -1.41% | ||
| 3 months | +44.97% | ||
| 6 months | +52.10% | ||
| Current year | +81.21% |
1 week
10.30
12.26
1 month
10.3012.26
Current year
5.1212.26
1 year
5.0514.64
3 years
5.0530.43
5 years
5.0530.43
10 years
5.0530.43
| Managers | Title | Age | Since |
|---|---|---|---|
Magnus Halle
FOU | Founder | 27 | 31/12/17 |
Theis Terwey
CEO | Chief Executive Officer | 48 | 31/12/17 |
Julie Ryan
DFI | Director of Finance/CFO | 38 | 31/12/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Duncan Moore
BRD | Director/Board Member | 65 | 23/09/21 |
| Founder | 55 | 31/12/17 | |
Michael Forer
BRD | Director/Board Member | 58 | 30/11/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 10.51 | +0.10% | 19,952 |
| 25/04/24 | 10.5 | -5.23% | 32,083 |
| 24/04/24 | 11.08 | -1.95% | 45,263 |
| 23/04/24 | 11.3 | -3.58% | 42,065 |
| 22/04/24 | 11.72 | +6.26% | 67,381 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.51
USD
Average target price
31.75
USD
Spread / Average Target
+202.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +81.21% | 547M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- GHRS Stock
